295 related articles for article (PubMed ID: 23469877)
1. Strategies for developing tuberculosis vaccines: emerging approaches.
Mollica A; Stefanucci A; Costante R
Curr Drug Targets; 2013 Aug; 14(9):938-51. PubMed ID: 23469877
[TBL] [Abstract][Full Text] [Related]
2. A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Guérin.
Woodworth JS; Clemmensen HS; Battey H; Dijkman K; Lindenstrøm T; Laureano RS; Taplitz R; Morgan J; Aagaard C; Rosenkrands I; Lindestam Arlehamn CS; Andersen P; Mortensen R
Nat Commun; 2021 Nov; 12(1):6658. PubMed ID: 34795205
[TBL] [Abstract][Full Text] [Related]
3. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and protective efficacy of DMT liposome-adjuvanted tuberculosis subunit CTT3H vaccine.
Teng X; Tian M; Li J; Tan S; Yuan X; Yu Q; Jing Y; Zhang Z; Yue T; Zhou L; Fan X
Hum Vaccin Immunother; 2015; 11(6):1456-64. PubMed ID: 25905680
[TBL] [Abstract][Full Text] [Related]
5. Developing whole mycobacteria cell vaccines for tuberculosis: Workshop proceedings, Max Planck Institute for Infection Biology, Berlin, Germany, July 9, 2014.
Whole Mycobacteria Cell Vaccines for Tuberculosis Summary Group
Vaccine; 2015 Jun; 33(26):3047-55. PubMed ID: 25882170
[TBL] [Abstract][Full Text] [Related]
6. Genome wide approaches discover novel Mycobacterium tuberculosis antigens as correlates of infection, disease, immunity and targets for vaccination.
Coppola M; Ottenhoff TH
Semin Immunol; 2018 Oct; 39():88-101. PubMed ID: 30327124
[TBL] [Abstract][Full Text] [Related]
7. Development of new vaccines and diagnostic reagents against tuberculosis.
Mustafa AS
Mol Immunol; 2002 Sep; 39(1-2):113-9. PubMed ID: 12213334
[TBL] [Abstract][Full Text] [Related]
8. Synthetic Long Peptide Derived from Mycobacterium tuberculosis Latency Antigen Rv1733c Protects against Tuberculosis.
Coppola M; van den Eeden SJ; Wilson L; Franken KL; Ottenhoff TH; Geluk A
Clin Vaccine Immunol; 2015 Sep; 22(9):1060-9. PubMed ID: 26202436
[TBL] [Abstract][Full Text] [Related]
9. Construction and evaluation of a multistage Mycobacterium tuberculosis subunit vaccine candidate Mtb10.4-HspX.
Niu H; Hu L; Li Q; Da Z; Wang B; Tang K; Xin Q; Yu H; Zhang Y; Wang Y; Ma X; Zhu B
Vaccine; 2011 Nov; 29(51):9451-8. PubMed ID: 22024175
[TBL] [Abstract][Full Text] [Related]
10. Immunization strategies against pulmonary tuberculosis: considerations of T cell geography.
Horvath CN; Xing Z
Adv Exp Med Biol; 2013; 783():267-78. PubMed ID: 23468114
[TBL] [Abstract][Full Text] [Related]
11. Multi-stage subunit vaccines against Mycobacterium tuberculosis: an alternative to the BCG vaccine or a BCG-prime boost?
Khademi F; Derakhshan M; Yousefi-Avarvand A; Tafaghodi M; Soleimanpour S
Expert Rev Vaccines; 2018 Jan; 17(1):31-44. PubMed ID: 29148853
[TBL] [Abstract][Full Text] [Related]
12. Fused Mycobacterium tuberculosis multi-stage immunogens with an Fc-delivery system as a promising approach for the development of a tuberculosis vaccine.
Mosavat A; Soleimanpour S; Farsiani H; Sadeghian H; Ghazvini K; Sankian M; Jamehdar SA; Rezaee SA
Infect Genet Evol; 2016 Apr; 39():163-172. PubMed ID: 26835592
[TBL] [Abstract][Full Text] [Related]
13. Tuberculosis vaccine development at a divide.
Kaufmann SH
Curr Opin Pulm Med; 2014 May; 20(3):294-300. PubMed ID: 24626237
[TBL] [Abstract][Full Text] [Related]
14. New tuberculosis vaccines.
Martín Montañés C; Gicquel B
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 1():57-62. PubMed ID: 21420568
[TBL] [Abstract][Full Text] [Related]
15. Novel vaccine candidates against Mycobacterium tuberculosis.
Khoshnood S; Heidary M; Haeili M; Drancourt M; Darban-Sarokhalil D; Nasiri MJ; Lohrasbi V
Int J Biol Macromol; 2018 Dec; 120(Pt A):180-188. PubMed ID: 30098365
[TBL] [Abstract][Full Text] [Related]
16. Differential proteomics approach to identify putative protective antigens of Mycobacterium tuberculosis presented during early stages of macrophage infection and their evaluation as DNA vaccines.
Sharma S; Rajmani RS; Kumar A; Bhaskar A; Singh A; Manivel V; Tyagi AK; Rao KV
Indian J Exp Biol; 2015 Jul; 53(7):429-39. PubMed ID: 26245027
[TBL] [Abstract][Full Text] [Related]
17. Tuberculosis vaccines: Opportunities and challenges.
Zhu B; Dockrell HM; Ottenhoff THM; Evans TG; Zhang Y
Respirology; 2018 Apr; 23(4):359-368. PubMed ID: 29341430
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice.
Li Q; Yu H; Zhang Y; Wang B; Jiang W; Da Z; Xian Q; Wang Y; Liu X; Zhu B
Scand J Immunol; 2011 Jun; 73(6):568-76. PubMed ID: 21323695
[TBL] [Abstract][Full Text] [Related]
19. Multiantigenic subunitary vaccines against tuberculosis in clinical trials: Where do we stand and where do we need to go?
Guapillo C; Hernández-Pando R; Flores-Valdez MA
Hum Vaccin Immunother; 2016 May; 12(5):1193-5. PubMed ID: 27049797
[TBL] [Abstract][Full Text] [Related]
20. The hunt for new tuberculosis vaccines: anti-TB immunity and rational design of vaccines.
Xing Z
Curr Pharm Des; 2001 Jul; 7(11):1015-37. PubMed ID: 11472252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
